VBI Vaccines Announces Dosing of First Patient in Second Phase II Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio

VBI Vaccines, Inc. announced that the first patient has been dosed in a second Phase IIa/IIb clinical study evaluating VBI-2601, an immunotherapeutic candidate targeting chronic hepatitis B virus.